Sign in

ADIA on OTC

Adia Med, Inc.

Adia Med, Inc. is an American medicinal chemicals and botanical products company.1 It is headquartered in Winter Park, Florida.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with AKANDA CORP., TFA Therapeutics, Inc. or China Foods Holdings Ltd., or pick any stock.

  • TickerADIA on OTC1
  • IndustryMedicinal Chemicals & Botanical Products1
  • HeadquartersWinter Park, Florida1
  • Incorporated inNV2
  • Business address4421 Gabriella Lane, Winter Park, Fl 327922
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

County, Nevada entered an Order Granting Application for Appointment of UMA LLC, (the “Order”), as Custodian of the Company.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

27.4%Gross margin4
-52.3%Operating margin4
-56.5%Net margin4
10879.7%Revenue growth, 20254
-$192.4KFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Sales Of Biologics brought in 37% of the revenue Adia Med, Inc. broke down this way in fiscal 2025.

  1. Sales Of Biologics$443.8K437%
  2. Biologics$289.6K424%
  3. Medical Procedures$245.6K420%
  4. Procedures$218.0K418%
  5. Shipping And Delivery$5.1K40%
  6. Sales Of Supplements$3.4K40%down 47% from 2024
  7. Supplements$1.3K40%down 69% from 2024
  8. Sales Of Ancillary Products$36040%
Products and services by year
Products and services20242025
Sales Of Biologics$0$443.8K
Biologics$0$289.6K
Medical Procedures$0$245.6K
Procedures$0$218.0K
Shipping And Delivery$0$5.1K
Sales Of Supplements$6.4K$3.4K
Supplements$4.2K$1.3K
Sales Of Ancillary Products$0$360

Business segments

Adia Labs brought in 64% of the revenue Adia Med, Inc. broke down this way in fiscal 2025.

  1. Adia Labs$448.9K464%
  2. Adia Med$246.0K435%
  3. Biolete$3.4K40%down 47% from 2024
  4. Corporate$2.3K40%
Business segments by year
Business segments20242025
Adia Labs$0$448.9K
Adia Med$0$246.0K
Biolete$6.4K$3.4K
Corporate$0$2.3K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue73¢$508.8K
  • Research and development4¢$29.1K
  • Other costs23¢$162.5K

Out of $700.5K in revenue.4 The company lost money this year.

Financial statements

Revenue4$700.5K in 2025+10880% since 2024
0$200.0K$400.0K$600.0K$800.0K2024: $6.4K$6.4K20242025: $700.5K$700.5K2025+10880%
Gross profit4$191.7K in 2025+8636% since 2024
0$50.0K$100.0K$150.0K$200.0K2024: $2.2K$2.2K20242025: $191.7K$191.7K2025+8636%
Operating income4-$366.5K in 2025+110% since 2024
-$400.0K-$300.0K-$200.0K-$100.0K02024: -$174.7K-$174.7K20242025: -$366.5K-$366.5K2025+110%
Net income4-$395.5K in 2025+118% since 2024
-$400.0K-$300.0K-$200.0K-$100.0K02024: -$181.1K-$181.1K20242025: -$395.5K-$395.5K2025+118%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Total Revenue$700.5K$6.4K
Total Cost of Revenue$508.8K$4.2K
Gross Profit$191.7K$2.2K
General and administrative$51.4K$30.0K
Advertising and promotion$78.2K$36.5K
Clinical trial fees$6.9K$0
Corporate filings$18.5K$0
Equipment leases$31.8K$0
Legal and professional fees$138.0K$68.6K
Licenses$2.7K$0
Public relations$16.8K$0
Repairs and maintenance$5.3K$0
Research and development$29.1K$0
Rent$64.6K$10.6K
Salaries and wages$61.8K$0
Shared-based compensation$42.2K$30.9K
Utilities$6.3K$0
Depreciation and amortization$4.4K$433
Total Operating Expenses$558.2K$176.9K
Profit (Loss) from Operations-$366.5K-$174.7K
Interest income$625$0
Sublease income$2.0K$0
Interest expense line of credit (related party)-$31.6K-$6.3K
Total Other Income (Expense)-$29.0K-$6.3K
Net Loss Before Provision for Income Taxes-$395.5K-$181.1K
Provision for Income Taxes$0$0
NET LOSS-$395.5K-$181.1K
Net Loss Per Share: Basic$0.00$0.00
Net Loss Per Share: Diluted$0.00$0.00
Weighted Average Number of Shares Outstanding: Basic93.6M shares91.7M shares
Weighted Average Number of Shares Outstanding: Diluted93.6M shares91.7M shares

Compare Adia Med, Inc. with another company

What it owns

What Adia Med, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$35.0K4 Dec 31, 2025$21.8K4 Dec 31, 2024+60.5%
Accumulated depreciation$4.3K4 Dec 31, 2025$1944 Dec 31, 2024+2134.5%
Property and equipment, net$30.7K4 Dec 31, 2025$21.6K4 Dec 31, 2024+41.9%
Finance-lease assets$108.2K4 Dec 31, 2025$130.3K4 Dec 31, 2024−17.0%
Operating-lease assets (leased space)$107.8K4 Dec 31, 2025$160.4K4 Dec 31, 2024−32.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$79.4K4 Dec 31, 2025$6.3K4 Dec 31, 2024+1155.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$04 Dec 31, 2025$5.9K4 Dec 31, 2024−100.0%
Finite-lived intangibles, gross$04 Dec 31, 2025$6.1K4 Dec 31, 2024−100.0%
Accumulated amortization$04 Dec 31, 2025-$2394 Dec 31, 2024+100.0%
Finite-lived intangibles, net$04 Dec 31, 2025$5.9K4 Dec 31, 2024−100.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$25.0K4 Dec 31, 2025$206.9K4 Dec 31, 2024−87.9%

Properties, in its own words

On November 1, 2024, the Company entered into a lease for 2,125 square feet of office space at 1561 W. Fairbanks Avenue, Winter Park, FL, 32789. This address is the Company’s principal place of business. The Company began occupying the space in January 2025 and this facility will be used as a medical clinic to perform treatments and procedures, for patients with autoimmune disorders, utilizing autologous hematopoietic stem cell transplantation (AHSCT) for multiple sclerosis.

As of the date of this report, the Company maintains a separate mailing address at 4421 Gabriella Lane, Winter Park, Florida, 32792.

Item 2 of the 10-K filed Mar 31, 2026.3

Leadership

Who has led Adia Med, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jason Scott Coombs2006–2008
  2. Tydus Richards2006
2010201520202025
Board members and other officers (2)

Former names

  • Adia Nutrition, Inc.Jul 22, 2013 to Aug 24, 20262
  • PivX Solutions, Inc.May 18, 2004 to Jul 17, 20132
  • DRILLING INCDec 26, 2001 to Apr 21, 20042

Timeline

  1. Oct 13, 20268-K Ended a material agreement9
  2. Oct 6, 20268-K Entered a material agreement; Completed an acquisition or sale10
  3. Oct 5, 20268-K Other events11
  4. Aug 24, 20268-K Entered a material agreement12
  5. Aug 17, 20268-K Bylaws or fiscal year changed13
  6. Jul 11, 2006New chief executive Tydus Richards becomes CEO8
  7. Jun 30, 2006New chief executive Jason Scott Coombs becomes CEO7

Filings

22 filings to the SEC since October 2021: 1 annual reports, 2 quarterly reports, 5 major events, 14 other. The latest 20:

  1. Oct 13, 20268-K CURRENT REPORT EDGAR
  2. Oct 6, 20268-K CURRENT REPORT EDGAR
  3. Oct 5, 20268-K CURRENT REPORT EDGAR
  4. Aug 24, 20268-K CURRENT REPORT EDGAR
  5. Aug 17, 20268-K CURRENT REPORT EDGAR
  6. Aug 13, 202610-Q FORM 10-Q FOR JUN 2026 EDGAR
  7. May 15, 202610-Q FORM 10-Q FOR MAR 2026 EDGAR
  8. Mar 31, 202610-K FORM 10-K FOR DEC 2025 EDGAR
  9. Dec 5, 202510-12G FORM 10-12(G) EDGAR
  10. Jun 24, 2024253G1 EDGAR
  11. Jun 21, 2024QUALIF EDGAR
  12. Jun 18, 2024CORRESP EDGAR
  13. Jun 18, 2024CORRESP EDGAR
  14. Jun 18, 20241-A/A EDGAR
  15. Jun 10, 2024CORRESP EDGAR
  16. Jun 10, 20241-A/A EDGAR
  17. Jun 5, 2024UPLOAD EDGAR
  18. May 24, 2024CORRESP EDGAR
  19. May 24, 20241-A/A EDGAR
  20. May 16, 2024UPLOAD EDGAR

The 22 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How Adia Med, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAdia Med, Inc.1
  • CIK0001160420
  • Employer ID (EIN)35-28296713
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2833 Medicinal Chemicals & Botanical Products1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4421 Gabriella Lane, Winter Park, FL 327921
  • Phone321-231-28431
  • Shares outstanding94,404,696 as of Aug 13, 20265
  • Public float$5.6M as of Jun 30, 20253
  • AuditorHaynie, Salt Lake City, Utah PCAOB ID 457; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceOct 23, 20011
  • Filings175 in all: 8-K (40), 4 (23), 3 (17), 10QSB (13), REGDEX (8), 10KSB/A (7), CORRESP (7), NT 10-Q (7)1
    All 32 form types

    8-K/A (6), NTN 10Q (6), UPLOAD (5), 1-A/A (4), 10KSB (4), 4/A (4), SC 13D (4), 10-Q (2), NT 10-K (2), NTN 10K (2), 1-A (1), 10-12G (1), 10-K (1), 10QSB/A (1), 10SB12G (1), 15F-12G (1), 253G1 (1), 3/A (1), DEF 14C (1), PRE 14C (1), QUALIF (1), REGDEX/A (1), SC 13D/A (1), SC 14F1 (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Latest 8-K (8-K) Oct 13, 2026

Risk factors and legal proceedings

The risks Adia Med, Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 32 risks under these headings, as written.3

  • We may not be successful in preventing the material adverse effects that any of the following risks and uncertainties may cause. These potential risks and uncertainties may not be a complete list of the risks and uncertainties facing us. There may be additional risks and uncertainties that we are presently unaware of, or presently consider immaterial, that may become material in the future and have a material adverse effect on us. You could lose all or a significant portion of your investment due to any of these risks and uncertainties.
  • Risks Related to Our Industry
  • Risks Related to Our Products
  • Our products participate in a market considered by many to represent new classes of therapy that the marketplace may not understand or accept. Furthermore, the success of our products is dependent on wider acceptance by the medical community and consumer understanding and acceptance.
  • Market acceptance of any future product candidates, if approved, will not be fully known until after they are launched and may be negatively affected by a potentially poor safety experience and the track record of other similar products and product candidates.
  • Risks Related to our Business and Strategy
  • We have incurred losses in the past and may not achieve consistent profitability for some time or at all.
  • The Company may require additional financing to maintain its reporting requirements and administrative expenses.
  • We rely on a third-party lab to provide us with the products we administer, market and sell. Interruptions in the supply of our products or inventory loss may adversely affect our business, results of operations and financial condition.
  • The FDA may conduct periodic inspections of HCT/P manufacturing facilities, and contract manufacturers’ facilities, to assess compliance with cGMP and other requirements.
  • The FDA may in the future determine that certain of our products that are, or are derived from, human cells or tissues, do not qualify for regulation solely under Section 361 of the PHSA, and may require that we revise our labeling and marketing claims for these products or that we suspend sales of such products until FDA pre-market clearance or approval is obtained, which could adversely affect our business, results of operations, and financial condition.
  • If any of our products cause or contribute to a death, serious injury, or adverse reaction, we will be required to report such death, serious injury, or adverse reaction under applicable HCT/P reporting regulations, and such events can result in voluntary corrective actions or agency enforcement actions.
The other 23 risks
  • Obtaining and maintaining any necessary regulatory approvals, including conducting clinical trials, for certain of our products or potential products could be expensive and time consuming.
  • We may be subject to fines, penalties, injunctions and other sanctions if we are deemed to be promoting our products for uses that require, but lack, regulatory approval.
  • Increased prices for, or unavailability of, raw materials used in our products could adversely affect our business, results of operations and financial condition.
  • We depend on our senior leadership team and may not be able to retain or replace these employees or recruit additional qualified personnel, which would harm our business, results of operations and financial condition.
  • We face the risk of product liability claims and may not be able to obtain or maintain adequate product liability insurance.
  • A cyberattack or significant disruptions of our information technology systems could adversely affect our business, results of operation and financial condition.
  • If a breach of our measures protecting personal data covered by HIPAA state privacy laws, or state data breach notification laws occurs, we may incur significant liabilities and operational disruptions.
  • Public health pandemics or outbreaks could adversely impact our business.
  • We will continue to incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.
  • Risks Related to the Ownership of Our Capital Stock
  • We have not and do not anticipate paying any dividends on our common stock.
  • We are subject to the reporting requirements of federal securities laws, this can be expensive and may divert resources from other projects, thus impairing our ability to grow.
  • If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate our business and investors’ views of us.
  • Due to our small number of employees and resources, and limited number of accounting personnel, the Company’s Board of Directors has four directors and does not have an audit committee or an independent audit committee financial expert we have limited segregation of duties, as a result, there would be insufficient independent review of duties performed.
  • The limited trading market for our common stock results in limited liquidity for shares of our common stock and significant volatility in our stock price.
  • Our Common Stock is currently deemed a “penny stock,” which makes it more difficult for our investors to sell their shares.
  • Offers or availability for sale of a substantial number of shares of our Common Stock may cause the price of our Common Stock to decline.
  • The market for our Common Stock may be thinly traded, so you may be unable to sell at or near ask prices or at all if you need to sell your shares to raise money or otherwise desire to liquidate your shares.
  • The availability of shares for sale in the future could reduce the market price of our Common Stock.
  • Because directors and officers currently and for the foreseeable future will continue to control the Company, it is not likely that you will be able to elect directors or have any say in the policies of the Company.
  • You may experience dilution of your ownership interests because of the future issuance of additional shares of our common stock.
  • You could lose all of your investment.
  • We are a “smaller reporting company” and will be exempt from certain disclosure requirements, which could make our common stock less attractive to potential investors.
  • Provisions of our Certificate of Incorporation, as amended, and Bylaws may delay or prevent a take-over which may not be in the best interests of our shareholders.

Legal proceedings

Recent proceedings are listed below.

Custodianship

This legal action is discussed in Item 1 under the title Custodian.

Cancellation of Shares

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
    SEC EDGAROther events
  12. 12
  13. 13